Financial

The device fans among us are always sad to see technology companies failing to thrive and no less so this time as what looks like a promising concept in Insulin pump design isn’t enough to stave off restructuring efforts.

St Jude agrees to a fixed forward royalty payments and to ongoing exclusive use of Kensey Nash’s Collagen in its AngioSeal device following mediated settlement.

Sorin’s Valve and CardioPulmonary Businesses were dragged down by Rhythm management, but overall 2011 sales held up and profits soared.

Orthofix’s financials are solid if unspectacular with healthy revenue growth in orthopaedics and sports medicine its shining stars.

Challenges for Integra as sales grows at slower rate than costs.

The Japanese way seems culturally at odds with the way many of Olympus’s overseas investors would like to see the company acting as it appoints board members from its creditor list.

Medical Devices are fuelling Germany’s rising export engine and the country’s Trade and Invest agency is rolling out the red carpet with R&D grants and commercialisation assistance.

Solid figures, but it’s not quite all good news at Medtronic as sales in some divisions suffer, especially in USA.

Despite losing Hemostase revenue, Cryolife has reported record Q4 and significant annual revenue growth, giving it optimistic outlook for the near term as it enacts global strategic initiatives.

Adherence to the EU Sharps Directive will result in adoption of premium priced products to prevent needlestick injury, according to Millennium Research Group.

Smith & Nephew’s 2011 was pretty good according to its financials and the company is getting a handle on its costs, suggesting a strong 2012, albeit at the expense of further job losses.

Abbott is sounding very pleased with itself about its drug-eluting stent sales figures, which it claims confirms its status as global market leader.

Stryker Corporation has announced that it’s Biotech division has reached a settlement with the U.S. Attorney’s Office for the District of Massachusetts, agreeing to pay a non-tax deductible fine of $15 million for one misdemeanour. Thirteen other felony charges will be dismissed.

Alphatec Holdings has settled with Biomet subsidiary Cross Medical over royalty dispute.

Despite a generally gloomy outlook Stryker financials and predictions for 2012 look strong from preliminary report.

Smith & Nephew is to form a joint venture with Essex Woodlands, a specialist healthcare growth equity and venture capital firm, to create a US-based joint venture with the goal of advancing its Biologics and Clinical Therapy solutions.